Directed Evolution of the Nonribosomal Peptide Synthetase BpsA to Enable Recognition by the Human Phosphopantetheinyl Transferase for Counter-Screening Antibiotic Candidates
journal contributionposted on 02.11.2020, 20:14 by Alistair S. Brown, Jack A. Sissons, Jeremy G. Owen, David F. Ackerley
Bacterial type II phosphopantetheinyl transferases (PPTases), required for the activation of many cellular mega-synthases, have been validated as promising drug targets in several pathogens. Activation of the blue-pigment-synthesizing nonribosomal peptide synthetase BpsA by a target PPTase can be used to screen in vitro for new antibiotic candidates from chemical libraries. For a complete screening platform, there is a need to also counter-screen inhibitors for cross-reactivity with the endogenous human Type II PPTase (hPPTase), as this is a likely source of toxicity. As hPPTase is unable to recognize the PCP-domain of native BpsA, we used a combination of directed evolution and rational engineering to generate a triple-substitution variant that is able to be efficiently activated by hPPTase. Our engineered BpsA variant was able to readily detect inhibition of both hPPTase and the equivalent rat PPTase by broad-spectrum PPTase inhibitors, demonstrating its potential for high-throughput counter-screening of novel antibiotic candidates.
Read the peer-reviewed publication
drug targetsscreening platformBpsA variantchemical librariesEnable Recognitiontarget PPTaseantibiotic candidatesbroad-spectrum PPTase inhibitorsHuman Phosphopantetheinyl Transferasenovel antibiotic candidatestype II phosphopantetheinyl transfe...Counter-Screening Antibiotic Candidateshigh-throughput counter-screeningcounter-screen inhibitorsType II PPTaseblue-pigment-synthesizing nonriboso...equivalent rat PPTaseNonribosomal Peptide Synthetase BpsAhPPTasetriple-substitution variant